Ho So
Overview
Explore the profile of Ho So including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jin Y, Cheng I, So H, Lai B, Ying S, Kwok K, et al.
Arthritis Rheumatol
. 2025 Mar;
PMID: 40083242
Objectives: This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by high-resolution peripheral quantitative computed tomography (HR-pQCT). Methods: This was a...
2.
Mok C, Leung M, Chan K, Ying K, Ho T, Lao W, et al.
Clin Exp Rheumatol
. 2025 Feb;
PMID: 39977029
Objectives: To study the safety and efficacy of tixagevimab-cilgavimab (TIX-CIL) in reducing COVID-19 in patients with rheumatic diseases receiving rituximab. Methods: Patients with rheumatic diseases who were receiving rituximab for...
3.
Lam W, Lau C, Luk H, Au L, Chan G, Chan W, et al.
Lancet Reg Health West Pac
. 2025 Feb;
55:101473.
PMID: 39944418
Background: Genome sequencing (GS) has revolutionised the diagnostic odyssey of patients with rare genetic diseases (RDs) and accelerated large-scale genome projects globally. However, the impact of GS on patients with...
4.
Parihar J, Gono T, So H, Gupta L
Int J Rheum Dis
. 2025 Jan;
28(1):e70084.
PMID: 39856794
No abstract available.
5.
Yap D, So H, Hamijoyo L, Kasitanon N, Chen D, Bae S, et al.
Int J Rheum Dis
. 2025 Jan;
28(1):e70022.
PMID: 39791498
No abstract available.
6.
Mok C, So H, Hamijoyo L, Kasitanon N, Chen D, Bae S, et al.
Int J Rheum Dis
. 2025 Jan;
28(1):e70021.
PMID: 39744836
The APLAR has published a set of recommendations on the management of systemic lupus erythematosus (SLE) in 2021. The current consensus paper supplements and updates specifically the treatment of lupus...
7.
Shi L, So H, Lam S, Li T, Li E, Szeto C, et al.
Ther Adv Musculoskelet Dis
. 2024 Dec;
16:1759720X241303314.
PMID: 39620049
Background: Hypertension (HTN) is the most important modifiable risk factor for the development of cardiovascular events (CVEs). Patients with axSpA are also associated with an increased risk of future CVE....
8.
Pang B, Iu E, Hang M, Chan W, Tse M, Yeung C, et al.
Redox Biol
. 2024 Nov;
78:103418.
PMID: 39531828
Idiopathic inflammatory myopathy (commonly known as myositis) is a group of immune-related diseases characterized by muscle damage, weakness, and fatigue with unknown causes. Although overactivated innate immunity is a widely...
9.
Jin Y, Cheng I, Wu D, Yan X, Lau S, Wong N, et al.
Ther Adv Musculoskelet Dis
. 2024 Oct;
16:1759720X241288060.
PMID: 39421802
Psoriatic arthritis (PsA) is a heterogeneous, chronic, inflammatory musculoskeletal disease that can lead to peripheral and axial damage and loss of function. A clear difference between PsA and other forms...
10.
Jin Y, Cheng I, So H, Li M, Cheuk Fung Yip T, Wong C, et al.
Int Immunopharmacol
. 2024 Oct;
143(Pt 1):113279.
PMID: 39357210
Objective: To investigate the correlation of serum protein biomarkers and disease activity in patients with PsA. Methods: 176 patients fulfilled the CASPAR (ClASsification criteria for Psoriatic ARthritis) were recruited in...